Cargando…
The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomogr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100081/ https://www.ncbi.nlm.nih.gov/pubmed/27751972 http://dx.doi.org/10.4274/mirt.97269 |
_version_ | 1782466064298278912 |
---|---|
author | Hasbek, Zekiye Doğan, Ömer Tamer Sarı, İsmail Yücel, Birsen Şeker, Mehmet Metin Turgut, Bülent Berk, Serdar Siliğ, Yavuz |
author_facet | Hasbek, Zekiye Doğan, Ömer Tamer Sarı, İsmail Yücel, Birsen Şeker, Mehmet Metin Turgut, Bülent Berk, Serdar Siliğ, Yavuz |
author_sort | Hasbek, Zekiye |
collection | PubMed |
description | OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUV(max)), SUV(av)e, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. METHODS: Serum anti-p53 Ab level was studied in three groups. Patients who underwent (18)F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent (18)F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. RESULTS: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUV(max), SUV(ave), TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). CONCLUSION: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion. |
format | Online Article Text |
id | pubmed-5100081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-51000812016-11-14 The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer Hasbek, Zekiye Doğan, Ömer Tamer Sarı, İsmail Yücel, Birsen Şeker, Mehmet Metin Turgut, Bülent Berk, Serdar Siliğ, Yavuz Mol Imaging Radionucl Ther Original Article OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUV(max)), SUV(av)e, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. METHODS: Serum anti-p53 Ab level was studied in three groups. Patients who underwent (18)F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent (18)F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. RESULTS: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUV(max), SUV(ave), TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). CONCLUSION: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion. Galenos Publishing 2016-10 2016-09-29 /pmc/articles/PMC5100081/ /pubmed/27751972 http://dx.doi.org/10.4274/mirt.97269 Text en © Molecular Imaging and Radionuclide Therapy, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hasbek, Zekiye Doğan, Ömer Tamer Sarı, İsmail Yücel, Birsen Şeker, Mehmet Metin Turgut, Bülent Berk, Serdar Siliğ, Yavuz The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title | The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title_full | The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title_fullStr | The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title_full_unstemmed | The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title_short | The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer |
title_sort | diagnostic value of the correlation between serum anti-p53 antibody and positron emission tomography parameters in lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100081/ https://www.ncbi.nlm.nih.gov/pubmed/27751972 http://dx.doi.org/10.4274/mirt.97269 |
work_keys_str_mv | AT hasbekzekiye thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT doganomertamer thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT sarıismail thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT yucelbirsen thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT sekermehmetmetin thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT turgutbulent thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT berkserdar thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT siligyavuz thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT hasbekzekiye diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT doganomertamer diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT sarıismail diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT yucelbirsen diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT sekermehmetmetin diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT turgutbulent diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT berkserdar diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer AT siligyavuz diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer |